NodThera’s pill lowered inflammation. The scales stayed put.

The most revealing detail in NodThera’s latest clinical announcement is a sentence a bathroom scale could understand: “There was no impact on body weight.” In a study involving people with and without type 2 diabetes, an experimental pill reduced inflammation. It did not make them lighter. For a company whose earlier mouse experiments had suggested an obesity opportunity, that distinction deserves the front page.

• The bet: oral medicines that inhibit NLRP3, a component of the cell’s inflammatory machinery.
• The result: RESOLVE-1 met its inflammation endpoint; the company reported no body-weight effect.
• The next test: a planned Phase 3 trial in peripheral artery disease, under the new name Rezera.

On September 9, 2026, NodThera became Rezera. Its lead molecule, once NT-0796, is now ruvonoflast. The renamed Boston biotech, with research and development in Cambridge, UK, is still pursuing the question that animated its beginnings: can selectively interrupting chronic inflammation change the course of disease?

The alarm inside the cell

Imagine an alarm designed to notice damage. Cholesterol crystals and misfolded proteins are among the danger signals that can activate NLRP3. The resulting inflammasome helps set inflammatory processes in motion, including the release of IL-1β and IL-18. An alarm is useful when something is wrong. Repeated activation can become part of the problem.

NodThera develops small molecules that act upstream of these signals. The attraction is an oral treatment affecting several downstream inflammatory mediators, rather than blocking just one cytokine. Its scientific ambition is selective control while preserving other infection-response pathways. That is a development rationale; long-term safety and clinical usefulness still need testing.

Location matters too. A compound circulating in blood has not necessarily reached the tissue where disease is unfolding. NodThera’s chemistry emphasizes penetration into tissues and the brain. That gives its pipeline a particular identity within the NLRP3 field, although brain penetration alone does not establish that one developer’s medicine will outperform another’s.

Ninety-five million dollars buys experiments

The company’s origins run through Polish drug-discovery research at Selvita and venture investor Epidarex Capital, which launched and seed-funded NodThera in 2016. This was a company assembled around a biological opportunity and chemistry, rather than a service looking for more customers. Alan Watt, now founder and chief scientific officer, supplied decades of pharmaceutical discovery experience.

In June 2018, NodThera announced a $40 million Series A, with Sofinnova Partners, 5AM Ventures, Epidarex and F-Prime participating. A $55 million Series B followed in June 2020, led by Novo Ventures and adding Cowen Healthcare Investments and Sanofi Ventures. Those figures describe capital raised in two rounds. They are not a bill for what the company has spent.

The 2020 financing supported a different lead candidate, NT-0167, then in Phase 1, plus additional discovery work. Today’s pipeline centers on ruvonoflast and trabzanoflast. The commercial proposition is ownership of investigational medicines developed toward approval and potential launch. Patients are intended beneficiaries; trial participants and investigators are current users of the research programs. There is no approved product here to order.

When the mice and the people disagree

In 2024, published experiments showed NT-0796 and NT-0249 reversing diet-induced obesity in mice. The work examined inflammation alongside fat reduction and compared the compounds with semaglutide and calorie restriction. That made obesity a plausible research direction. It did not turn an animal result into a human treatment.

RESOLVE-1 supplied a more demanding test: 176 participants, randomized treatment, placebo control and 24 weeks of observation. The company’s September 2026 topline report said both tested ruvonoflast regimens reduced high-sensitivity C-reactive protein relative to placebo. It also reported reductions in other inflammatory biomarkers, generally good tolerability, and no body-weight effect. Detailed findings were scheduled for a November scientific presentation.

The interpretive lesson is quite practical. A molecule can perform on one outcome while disappointing expectations on another. The mouse findings and human results should be kept in separate columns. RESOLVE-2 asks a further question about ruvonoflast alongside semaglutide; its results were expected in the fourth quarter of 2026.

The next question is in the legs

Rezera’s stated next destination is peripheral artery disease, where narrowed arteries reduce blood flow to the limbs, commonly the legs. The company plans to begin Phase 3 in the first half of 2027. The human anti-inflammatory signal supports that plan. Whether lowering biomarkers improves function or disease outcomes remains the consequential question.

“Lengthy enrollment in registrational cardiovascular studies delays answers for the patients who need them.”Jyothis George, chief medical officer / September 2026

One useful operational idea is REVEAL-PAD, a planned observational study preceding the interventional program. Rezera intends to characterize inflammation, establish clinical sites and identify people who might qualify for future trials. Scientists from Colorado Prevention Center Clinical Research and Duke Clinical Research Institute join its steering committee; the Global PAD Association is supporting patient engagement. Other developers can copy the preparation: understand the population before asking it to enroll.

A second molecule crosses the border

Meanwhile, trabzanoflast, previously NT-0150, pursues neuroinflammatory disease. On September 30, Rezera reported Phase 1 results in 55 healthy participants, including cerebrospinal-fluid sampling that supported high central nervous system exposure. The study concerned tolerability, pharmacology and target engagement. It was not evidence of treating a neurological disease.

Competitors such as Ventus are also developing brain-penetrant NLRP3 inhibitors. NodThera’s distinction rests on its molecules, their tissue exposure and its clinical choices, rather than exclusive possession of the target. Its careers page describes openness and honest debate. The latest results make that a sensible aspiration: biology has a habit of correcting the presentation.

For readers, the useful habit is to ask which endpoint moved, in which population, over what period. For patients, the practical route is trial information and eligibility, not a purchase button. This approach would disappoint if biomarker changes failed to improve meaningful outcomes, if safety limited dosing, or if the selected disease were insufficiently driven by NLRP3. The next experiments must earn the next claims.